Oncotarget is a valuable national and international multi-disciplinary bio-medical journal. This notable medical and research publication is published by prominent scientists, covering topics like aging, autophagy, chromosome research, immunology, microbiology, oncology, and pathology. Oncotarget allows researchers to submit their life-saving findings on various diseases for a more widely availability for scientific dissemination. The scientific articles printed in this journal helps to makes scientific results more widely and rapidly available to global researchers, practitioners, and the public. The good news for its readers is that Oncotarget will continue to be published twice-weekly on PubMed to advance the process for indexing. Learn more about Oncotarget at Research Gate.
Oncotarget continues to be published on open source repositories like Web of Science/ISI citation databases such as Biological Abstracts, BIOSIS Previews, EMBASE, PubMed, PubMed Central, Science Citation Index Expanded, and Scopus. According to the National Library of Medicine, Oncotarget has met its goal which was to be the only research journal to submit whole issues of articles to PubMed almost immediately after being published online. The scientific articles accepted by Oncotarget are published with a DOI (direct object identifier) and affixes the recommendations of the COPE (Committee on Publication Ethics) to each published oeuvres. As soon as issue and page numbers are assigned, they are categorized, indexed, and published in perpetuum published in PubMed. Check Oncotarget journal at scimagojr.com
In September 2017, PubMed began their collaboration with Oncotarget by publishing Volume 8 – Issues 31 to 34 and then Issue 35 to 36. The Office of External and Legal Affairs of Oncotarget stated that it is their mission to meet the 21st century medical challenges as a scholarly journal by scientists for scientists and for all to read. The legal office also said that publishing Oncotarget articles on PubMed helps to do away with any boundaries that exist between biomedical specialists and to further enhance research through intelligent and professional reviews. It is viewed that Oncotarget remains a vital resource in research covering the progress of science to hopefully see individual lives free of disease.
— Oncotarget (@OncotargetJrnl) December 5, 2017